

Novel Process for the Production of **IMEGLIMIN**

Process Highlights

- ✓ Reusable novel Heterogeneous Catalyst
- ✓ 100% Key Starting Material conversion
- ✓ Highly selective (97%) process
- ✓ High Racemic yields (up to 85%)
- ✓ Less effluent discharge
- ✓ Reduced reaction time
- ✓ Reusable solvent



IMEGLIMIN
Metformin Substitute:
Type-2 Diabetes
Treatment

Technology Available For Licensing/ Co-development

Background

- India's Type-2 diabetes cases may reach 134 million by 2045
- Prolonged use of Metformin can cause gastro intolerance & vit B-12 deficiency
- Imeglimin (TWYMEEG®), a novel & safer alternative, was launched in Japan.
- Our technology offering improves its synthesis & economics by addressing existing issues of solubility limitations, longer reaction time, more down-streaming steps & water footprints etc.

Value Proposition

- Inexpensive heterogeneous catalyst
- Scalable & Cost-effective Process
- Racemic Yield of up to 85%
- Significant reduction in wastewater Generation
- Improved solubility limitations
- Less Downstreaming steps

MARKET

- TWYMEEG® net sales in Japan has reached JPY 5 billion (USD 33 million) in 2024
- India has approved Imeglimin in January 2023

Technology Offering

Reusable Heterogeneous Catalyst

Batch Size: 10 kg

Reduced water footprint

Racemic Yield 85%

Efficient downstream protocol

Reusable Solvent

Application:
Treatment of Type-2 Diabetes

IP: PCT/IN2025/050724